← Back to Search

Procedure

Dispersion Ablation + PVI, VX1, PVI for Atrial Fibrillation (Tailored-AF Trial)

N/A
Waitlist Available
Research Sponsored by Volta Medical
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Tailored-AF Trial Summary

This trial tests a new, tailored way of performing ablation for atrial fibrillation against the standard method.

Tailored-AF Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Freedom from documented AF after one ablation procedure
Secondary outcome measures
Freedom from documented AF/AT after one ablation procedure
Freedom from documented AF/AT after one or two ablation procedures
Incidence of complications (safety composite endpoint)

Tailored-AF Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: TailoredExperimental Treatment2 Interventions
Tailored ablation strategy
Group II: AnatomicalActive Control1 Intervention
Anatomical ablation strategy

Find a Location

Who is running the clinical trial?

Volta MedicalLead Sponsor
4 Previous Clinical Trials
682 Total Patients Enrolled
4 Trials studying Atrial Fibrillation
682 Patients Enrolled for Atrial Fibrillation
CardiaBaseOTHER
3 Previous Clinical Trials
1,141 Total Patients Enrolled
CovanceIndustry Sponsor
119 Previous Clinical Trials
12,439 Total Patients Enrolled
1 Trials studying Atrial Fibrillation
28 Patients Enrolled for Atrial Fibrillation

Media Library

Dispersion ablation + PVI (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT04702451 — N/A
Atrial Fibrillation Research Study Groups: Tailored, Anatomical
Atrial Fibrillation Clinical Trial 2023: Dispersion ablation + PVI Highlights & Side Effects. Trial Name: NCT04702451 — N/A
Dispersion ablation + PVI (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04702451 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the scope of individuals participating in this investigation?

"To move forward with this research project, 374 suitable volunteers are required. Washington University in Saint Louis, Missouri and Kansas City Heart Rhythm Institute in Overland Park, Kansas are two of the many sites where participants may enroll."

Answered by AI

Are there any available positions in this trial that participants can fill?

"Confirmed. The information available on clinicaltrials.gov affirms that this medical experiment is still seeking participants, as it was first posted on February 12th 2021 and updated lastly on May 12th 2022. 374 individuals will be recruited from 9 distinct sites for the study's duration."

Answered by AI

How many centers are currently managing this experiment?

"Nine locations have opened recruitment for this trial, such as Washington University in Saint Louis, Kansas City Heart Rhythm Institute in Overland Park, and Grandview Medical Center in Birmingham. Additional sites are also available."

Answered by AI
~90 spots leftby Apr 2025